Stockscreener 앱 받기
17.05
0.03%
-0.02
전일 마감가:
$17.03
열려 있는:
$17.05
하루 거래량:
3.30M
Relative Volume:
0.54
시가총액:
$19.29B
수익:
$16.77B
순이익/손실:
$-959.00M
주가수익비율:
-8.525
EPS:
-2
순현금흐름:
$1.37B
1주 성능:
+1.64%
1개월 성능:
-6.35%
6개월 성능:
+2.62%
1년 성능:
+83.66%
1일 변동 폭
$16.90
$17.17
1주일 범위
$16.15
$17.17
52주 변동 폭
$9.35
$19.31
테바 ADR Stock (TEVA) Company Profile
명칭
Teva Pharmaceutical Industries Ltd Adr
전화
972 (3) 914-8213
주소
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV
TEVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| TEVA | 17.04 | 19.29B | 16.77B | -959.00M | 1.37B | -2.00 |
| ZTS | 177.22 | 79.33B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.545 | 43.04B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.29 | 42.13B | 30.27B | 1.93B | 3.45B | 0.444 |
| VTRS | 13.24 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
테바 ADR Stock (TEVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-10 | 업그레이드 | Argus | Hold → Buy |
| 2024-03-08 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2024-02-12 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-23 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-01-03 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-12-18 | 개시 | HSBC Securities | Buy |
| 2023-11-27 | 업그레이드 | UBS | Neutral → Buy |
| 2023-07-06 | 업그레이드 | UBS | Sell → Neutral |
| 2023-05-25 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-05-18 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-01-19 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-11-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-11-04 | 다운그레이드 | UBS | Neutral → Sell |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-08-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-06-14 | 재개 | UBS | Neutral |
| 2022-05-17 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-05-04 | 다운그레이드 | Piper Sandler | Neutral → Underweight |
| 2022-04-05 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2022-03-25 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
| 2022-01-27 | 다운그레이드 | Argus | Buy → Hold |
| 2021-10-28 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2021-05-04 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2020-11-25 | 개시 | Oppenheimer | Perform |
| 2020-08-06 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2020-07-27 | 재개 | Goldman | Neutral |
| 2020-06-01 | 업그레이드 | SunTrust | Hold → Buy |
| 2020-04-24 | 재개 | Citigroup | Neutral |
| 2020-04-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-02-24 | 다운그레이드 | Edward Jones | Hold → Sell |
| 2019-11-12 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2019-10-17 | 업그레이드 | Gabelli & Co | Hold → Buy |
| 2019-08-07 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-19 | 개시 | Wolfe Research | Peer Perform |
| 2019-07-15 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2019-07-10 | 재개 | Credit Suisse | Neutral |
| 2019-07-05 | 업그레이드 | Argus | Hold → Buy |
| 2019-06-11 | 개시 | Barclays | Underweight |
| 2019-06-03 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2019-05-30 | 다운그레이드 | BofA/Merrill | Buy → Underperform |
| 2019-05-28 | 다운그레이드 | UBS | Buy → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2019-03-07 | 재개 | UBS | Buy |
모두보기
테바 ADR 주식(TEVA)의 최신 뉴스
Such Is The Power Of CNH Industrial NV (NYSE: CNH) - Stocks Register
Zollinger-Ellison Syndrome (Gastrinoma) Global Clinical Trials Review 2024: Country (G7 & E7), Phase, Trial Status, End Points Status and Sponsor Type - GlobeNewswire Inc.
Where Do Analysts See Teva- Pharmaceutical Industries Ltd. ADR (NYSE: TEVA) Heading? - Stocks Register
Biliary Tract Cancer Market Research Report 2024-2030 with Analyst Recommendations - GlobeNewswire Inc.
South Africa Central Nervous System Therapeutic Market Size & Outlook, 2028 - Grand View Research
Spain Head And Neck Cancer Therapeutics Market Size & Outlook, 2030 - Grand View Research
Vontobel Holding Ltd. Sells 332,717 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) - MarketBeat
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 5.28 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: The Story of a 52-Week Stock Range - The InvestChronicle
Ophthalmic Disease Therapeutics Market Analysis by Age-related Macular Degeneration, Diabetic Macular Edema, & Other Retinal Disorders - GlobeNewswire Inc.
Weekly Upgrades and Downgrades - InvestorPlace
Monitoring Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insider movements - Knox Daily
Views of Wall Street’s Leading Experts on Teva- Pharmaceutical Industries Ltd. ADR - SETE News
Selling Buzz: Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial Daniell Richard sells 98,943 shares of the company – Knox Daily - Knox Daily
Qifu Technology Inc. ADR (QFIN) gets rating Initiated from Nomura - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Is Currently 1.45 below its 200 Period Moving Avg: What Does This Mean? – The DBT News - The DBT News
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) Stock: Exploring a Year of Highs, Lows, and Trading Volume - The InvestChronicle
Keeping an Eye on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) After Insider Trading Activity - Knox Daily
TEVA’s current quarter earnings: What analysts forecast? - US Post News
Taking a look at what insiders are doing to gauge the Teva- Pharmaceutical Industries Ltd. ADR (TEVA)’s direction - Knox Daily
HP Stock Sees Surge of Approximately 3.50% in Last Five Days - Knox Daily
RPM International, Inc. [RPM] Shares Rise 6.30 % on Wednesday - Knox Daily
Alight Inc. (ALIT) gets rating Downgrade from JP Morgan - Knox Daily
TEVA’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - The InvestChronicle
Keycorp (NYSE: KEY) Up 50.91% This Year: What Is Going To Happen Next - Stocks Register
Argus upgrades Teva- Pharmaceutical Industries Ltd. ADR (TEVA) rating to a Buy - Knox Daily
TE Connectivity Ltd’s latest rating changes from various analysts - Knox Daily
FTCI’s latest rating updates from top analysts. - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR (TEVA): Worth A Small Bite At $17.54 - Stocks Register
How will Teva- Pharmaceutical Industries Ltd. ADR’s (TEVA) earnings compare to estimates this quarter? - US Post News
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Shares Jump Approximately 70.34% Over the Year - Knox Daily
Before You Invest, Make Sure You Check This New Oriental Education & Technology Group Inc. ADR (NYSE: EDU) Analysis – Stocks Register - Stocks Register
TEVA’s Market Flip-Flop: Exploring the Volatility of 2023 Performance - The InvestChronicle
Does Walmart Inc (NYSE: WMT) Still Need To Convince Analysts? - Stocks Register
When Would Be The Best Time To Buy UiPath Inc (NYSE: PATH) Stock? - Stocks Register
Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Stock trading around $17.72 per share: What’s Next? - The DBT News
Checking in on Teva- Pharmaceutical Industries Ltd. ADR (TEVA) after recent insiders movement - Knox Daily
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY (risperidone) Extended-Release Injectable Suspension from Perseris (RBP-7000) - wallstreet:online
DLTR Shares Experience Surge in Value - Knox Daily
A company insider recently sold 708 shares of NAPCO Security Technologies Inc [NSSC]. Should You Sale? - Knox Daily
TEVA Shares Experience Surge in Value - Knox Daily
Does Teva- Pharmaceutical Industries Ltd. ADR (TEVA) offer a good opportunity for investors? - SETE News
How analysts predict Teva- Pharmaceutical Industries Ltd. ADR (TEVA) will perform this quarter? - US Post News
Argus analysts upgrades a Buy rating for Teva- Pharmaceutical Industries Ltd. ADR (TEVA) - Knox Daily
Teva- Pharmaceutical Industries Ltd. ADR Inc. (TEVA) Price Performance: The Role of Share Buybacks and Stock Splits - The InvestChronicle
What will the future hold for Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) stock? - US Post News
Insider Selling: Daniell Richard, Teva- Pharmaceutical Industries Ltd. ADR [TEVA] Exec. VP, European Commercial divested 98,943 shares – Knox Daily - Knox Daily
insider CHURAY DANIEL J sale 16,975 shares of MRC Global Inc [MRC] - Knox Daily
The United States Erythropoietin Drugs Market Size & Outlook, 2030 - Grand View Research
테바 ADR (TEVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.08%
1.19%
자본화:
|
볼륨(24시간):